Godavari Biorefineries secures Chinese patent for novel anti-cancer molecule

22 Jul 2025 Evaluate

Godavari Biorefineries, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China’s patent and trademark office for its novel anti-cancer molecule - HYDROXY-1, 4-NAPHTHALENEDIONE. 

This patent covers a novel class of compounds that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer. 

The company’s clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, the company is deepening its focus in translational research that addresses some of the world’s most urgent health challenges. 

Godavari Biorefineries is one of the manufacturers of ethanol based chemicals in India. Its diversified product portfolio comprises of bio-based chemicals, sugar, different grades of ethanol and power.

Godavari Biorefin Share Price

245.90 6.15 (2.57%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Shree Renuka Sugar 26.49
Bajaj Hindusthan Sug 19.58
Triveni Engg. & Inds 350.10
Balrampur Chini Mill 444.50
Dalmia Bharat Sugar 294.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×